
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina is viewed favorably because its clinical sequencing franchise is inflecting, with oncology-led demand, improving reimbursement, and repeated catalysts in MRD, tumor profiling, colorectal cancer blood tests, and multi-cancer detection supporting durable mid-teens growth. The company also appears well positioned to defend and expand share through a leading cost basis, high consumables gross margins above 70%, strong instrument demand for NovaSeq X, and sticky customer relationships that raise switching costs in clinical workflows. Beyond core sequencing, BioInsight could add a new growth vector through licensing or subscriptions, while the market’s premium valuation is supported by stronger sales acceleration and a path to margin leverage as new products scale.
Bears say
Illumina is facing a fundamentally challenged demand backdrop, as clinical growth may not be sustainable, academic spending remains weak, and research and applied sequencing consumables ex-China are expected to decline in 2026. Its core economics are under pressure from customer-driven deflation in per-sample unit economics, while the shift from NovaSeq 6000 to NovaSeq X is weighing on core revenue, consumables revenue, instrument margins, and overall gross margins. At the same time, China risk remains elevated because the company is still on the unreliable entities list, sales there have fallen from 10% a few years ago to about 5% of 2026 sales, and intensified competition from Roche, MGI, private firms, and long-read peers threatens share.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Illumina (ILMN) Forecast
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares